Cargando…
Development of cyclosporin A mediated immunity in L1210 leukaemia.
Cyclosporin A (CsA) is an effective modulator of multidrug resistance (MDR) in vitro and in murine tumour systems in vivo. We now report the production of immunity to L1210 leukaemia by the addition of CsA to VP-16 therapy of leukaemic BDF/1 mice. VP-16/cyclosporin A tumour immunity induction arises...
Autores principales: | Slater, L. M., Wetzel, M., Cho, J., Sweet, P. |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
1991
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1977840/ https://www.ncbi.nlm.nih.gov/pubmed/1764373 |
Ejemplares similares
-
Adriamycin/cyclophosphamide and adriamycin/melphalan in advanced L1210 leukaemia.
por: Tobias, J. S., et al.
Publicado: (1975) -
Characterization of a monoclonal antibody to L1210 leukaemia.
por: Testorelli, C., et al.
Publicado: (1982) -
Influence of micrococcus, BCG and related polysaccharides on the proliferation of the L1210 leukaemia.
por: Verloes, R., et al.
Publicado: (1978) -
Effect of VM-26 on the haematological responses of mice to L1210 leukaemia.
por: Hacker, M., et al.
Publicado: (1980) -
Active immunotherapy of L1210 leukaemia applied after the graft of tumour cells.
por: Mathé, G., et al.
Publicado: (1969)